Vasopeptidase inhibitors: an emerging class of cardiovascular drugs

被引：45
作者：
Bralet, J [1 ]
Schwartz, JC
机构：
[1] Univ Dijon, Fac Pharm, F-21033 Dijon, France
[2] INSERM, Ctr Paul Broca, Inst Univ France, F-75014 Paris, France
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2001年 / 22卷 / 03期
关键词：
D O I：
10.1016/S0165-6147(00)01644-8
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Vasopeptidase inhibitors (VPIs) inhibit both angiotensin-converting enzyme (ACE) and neprilysin (NEP) and can thus reduce the activity of the renin-angiotensin system and potentiate the vasodilatory, natriuretic and antiproliferative effects of bradykinin and natriuretic peptides, In preclinical studies, VPIs display a large profile being effective in all tested models of hypertension and in heart failure, and ongoing clinical studies suggest th at VPIs possess advantages over other therapies.
引用
收藏
页码：106 / 109
页数：6
相关论文
共 26 条
[11]   PROTECTION OF ATRIAL NATRIURETIC FACTOR AGAINST DEGRADATION - DIURETIC AND NATRIURETIC RESPONSES AFTER INVIVO INHIBITION OF ENKEPHALINASE (EC 3.4.24.11) BY ACETORPHAN [J].
GROS, C ;
SOUQUE, A ;
SCHWARTZ, JC ;
DUCHIER, J ;
COURNOT, A ;
BAUMER, P ;
LECOMTE, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (19) :7580-7584
[12]   DUAL MECHANISM OF ANGIOTENSIN-II INHIBITS ANP-INDUCED MESANGIAL CGMP ACCUMULATION [J].
HANEDA, M ;
KIKKAWA, R ;
MAEDA, S ;
TOGAWA, M ;
KOYA, D ;
HORIDE, N ;
KAJIWARA, N ;
SHIGETA, Y .
KIDNEY INTERNATIONAL, 1991, 40 (02) :188-194
[13]  
Hu K, 1999, CARDIOVASC RES, V41, P503
[14]   Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans [J].
Laurent, S ;
Boutouyrie, P ;
Azizi, M ;
Marie, C ;
Gros, C ;
Schwartz, JC ;
Lecomte, JM ;
Bralet, J .
HYPERTENSION, 2000, 35 (05) :1148-1153
[15]   Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction [J].
Marie, C ;
Mossiat, C ;
Gros, C ;
Schwartz, JC ;
Lecomte, JM ;
Bralet, J .
CARDIOVASCULAR RESEARCH, 1999, 41 (03) :544-553
[16]   The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure [J].
McClean, DR ;
Ikram, H ;
Garlick, AH ;
Richards, AM ;
Nicholls, MG ;
Crozier, IG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) :479-486
[17]   The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides [J].
McDowell, G ;
Coutie, W ;
Shaw, C ;
Buchanan, KD ;
Struthers, AD ;
Nicholls, DP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (03) :329-332
[18]   Vasopeptidase inhibition and angio-oedema [J].
Messerli, FH ;
Nussberger, J .
LANCET, 2000, 356 (9230) :608-609
[19]   Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects [J].
Norton, GR ;
Woodiwiss, AJ ;
Hartford, C ;
Trifunovic, B ;
Middlemost, S ;
Lee, A ;
Allen, MJ .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (06) :563-571
[20]   Plasma bradykinin in angio-oedema [J].
Nussberger, J ;
Cugno, M ;
Amstutz, C ;
Cicardi, M ;
Pellacani, A ;
Agostoni, A .
LANCET, 1998, 351 (9117) :1693-1697
123